Cargando…

Oral curcumin supplementation in patients with atopic asthma

Oral curcumin is recognized to have anti-inflammatory properties and has been used by ancient traditional medicine for centuries to treat a variety of diseases. In vitro studies have confirmed the ability of curcumin to inhibit allergic inflammatory cytokine responses from lymphocytes; however, ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Dennis H., Phillips, Joshua F., Lockey, Richard F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: OceanSide Publications, Inc. 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3390116/
https://www.ncbi.nlm.nih.gov/pubmed/22852117
http://dx.doi.org/10.2500/ar.2011.2.0016
_version_ 1782237404544892928
author Kim, Dennis H.
Phillips, Joshua F.
Lockey, Richard F.
author_facet Kim, Dennis H.
Phillips, Joshua F.
Lockey, Richard F.
author_sort Kim, Dennis H.
collection PubMed
description Oral curcumin is recognized to have anti-inflammatory properties and has been used by ancient traditional medicine for centuries to treat a variety of diseases. In vitro studies have confirmed the ability of curcumin to inhibit allergic inflammatory cytokine responses from lymphocytes; however, there are no in vivo studies of curcumin to treat inflammation associated with allergic asthma. This study was designed to determine the effect of oral curcumin supplementation on patients with stable, persistent, atopic asthma. Adult patients with stable, persistent asthma with evidence of allergic sensitization were randomized to receive 1000 mg of curcumin twice daily or placebo. Subjects were followed for 6 months and performed monthly spirometry (pre- and postbronchodilator); Asthma Control Test (ACT) scoring; and measurements for fractional excretion of nitric oxide (NO), serum eosinophil count, leukocyte count, total IgE, specific IgE to Dermatophagoides pteronyssinus (Der p) and Dermatophagoides farinae (Der f), use of rescue albuterol, and dose of inhaled corticosteroid. Nine patients were randomized into the treatment arm and six were randomized into the placebo group. No differential response was seen in the treatment and placebo groups regarding the primary end point, postbronchodilator forced expiratory volume in 1 second (FEV(1)). Similarly, all secondary end point evaluations were not significantly different. Despite in vitro evidence that curcumin has anti-inflammatory properties and can inhibit allergic cytokine responses from lymphocytes in vitro, curcumin, 1000-mg, twice daily supplementation did not significantly affect postbronchodilator FEV(1), ACT scores, use of rescue bronchodilator, dose of inhaled corticosteroid, exhaled NO, serum IgE, total white blood cell count specific IgE to Der p or Der f, and blood eosinophils in patients with persistent atopic asthma.
format Online
Article
Text
id pubmed-3390116
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher OceanSide Publications, Inc.
record_format MEDLINE/PubMed
spelling pubmed-33901162012-07-31 Oral curcumin supplementation in patients with atopic asthma Kim, Dennis H. Phillips, Joshua F. Lockey, Richard F. Allergy Rhinol (Providence) Articles Oral curcumin is recognized to have anti-inflammatory properties and has been used by ancient traditional medicine for centuries to treat a variety of diseases. In vitro studies have confirmed the ability of curcumin to inhibit allergic inflammatory cytokine responses from lymphocytes; however, there are no in vivo studies of curcumin to treat inflammation associated with allergic asthma. This study was designed to determine the effect of oral curcumin supplementation on patients with stable, persistent, atopic asthma. Adult patients with stable, persistent asthma with evidence of allergic sensitization were randomized to receive 1000 mg of curcumin twice daily or placebo. Subjects were followed for 6 months and performed monthly spirometry (pre- and postbronchodilator); Asthma Control Test (ACT) scoring; and measurements for fractional excretion of nitric oxide (NO), serum eosinophil count, leukocyte count, total IgE, specific IgE to Dermatophagoides pteronyssinus (Der p) and Dermatophagoides farinae (Der f), use of rescue albuterol, and dose of inhaled corticosteroid. Nine patients were randomized into the treatment arm and six were randomized into the placebo group. No differential response was seen in the treatment and placebo groups regarding the primary end point, postbronchodilator forced expiratory volume in 1 second (FEV(1)). Similarly, all secondary end point evaluations were not significantly different. Despite in vitro evidence that curcumin has anti-inflammatory properties and can inhibit allergic cytokine responses from lymphocytes in vitro, curcumin, 1000-mg, twice daily supplementation did not significantly affect postbronchodilator FEV(1), ACT scores, use of rescue bronchodilator, dose of inhaled corticosteroid, exhaled NO, serum IgE, total white blood cell count specific IgE to Der p or Der f, and blood eosinophils in patients with persistent atopic asthma. OceanSide Publications, Inc. 2011 /pmc/articles/PMC3390116/ /pubmed/22852117 http://dx.doi.org/10.2500/ar.2011.2.0016 Text en Copyright © 2011, OceanSide Publications, Inc., U.S.A. This publication is provided under the terms of the Creative Commons Public License ("CCPL" or "License"), in attribution 3.0 unported (Attribution Non-Commercial No Derivatives (CC BY-NC-ND)), further described at: http://creativecommons.org/license/by-nc-nd/3.0/legalcode. The work is protected by copyright and/or other applicable law. Any use of the work other then as authorized under this license or copyright law is prohibited.
spellingShingle Articles
Kim, Dennis H.
Phillips, Joshua F.
Lockey, Richard F.
Oral curcumin supplementation in patients with atopic asthma
title Oral curcumin supplementation in patients with atopic asthma
title_full Oral curcumin supplementation in patients with atopic asthma
title_fullStr Oral curcumin supplementation in patients with atopic asthma
title_full_unstemmed Oral curcumin supplementation in patients with atopic asthma
title_short Oral curcumin supplementation in patients with atopic asthma
title_sort oral curcumin supplementation in patients with atopic asthma
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3390116/
https://www.ncbi.nlm.nih.gov/pubmed/22852117
http://dx.doi.org/10.2500/ar.2011.2.0016
work_keys_str_mv AT kimdennish oralcurcuminsupplementationinpatientswithatopicasthma
AT phillipsjoshuaf oralcurcuminsupplementationinpatientswithatopicasthma
AT lockeyrichardf oralcurcuminsupplementationinpatientswithatopicasthma